Oruka Therapeutics, Inc. (ORKA)
Healthcare • Biotechnology
StockNasdaqGMUnited StatesUS6876041087
Kyvero is an independent information site. It is not affiliated with, endorsed by or sponsored by Oruka Therapeutics, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in USD. Dividends, results and news are marked on the day they happened; click a day to see them.
Updated 13 Nov 2026 16:28. Information, not advice. Showing the last 12 months. Create a free account to see the whole history
Results
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 11 Mar 2027 16:00 | -0.74 | — | — | Upcoming |
| 09 Nov 2026 16:00 | -0.63 | -0.63 | -0.6% | In line |
| 10 Aug 2026 07:00 | -0.50 | -0.55 | -10.0% | Miss |
| 13 May 2026 16:00 | -0.54 | -0.48 | +10.6% | Beat |
| 12 Mar 2026 16:00 | -0.62 | -0.45 | +26.9% | Beat |
| 12 Nov 2025 16:00 | -0.52 | -0.55 | -5.0% | Miss |
| 11 Aug 2025 16:00 | -0.43 | -0.46 | -6.4% | Miss |
| 14 May 2025 16:00 | -0.44 | -0.40 | +9.1% | Beat |
| 06 Mar 2025 16:00 | -0.41 | -0.49 | -18.6% | Miss |
| 13 Nov 2024 16:00 | -0.32 | -1.46 | -351.6% | Miss |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 0 | — | -105.4M | — | -1.85 | — | -88.4M |
| 2024 | — | — | — | — | — | — | — |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| Nov 2026 In progress | 98.85 | 113.24 | 94.05 | 103.49 | +6.83% | 10,525,586 | |
| Oct 2026 | 82.85 | 98.88 | 70.50 | 96.87 | +16.30% | 19,737,100 | |
| Sep 2026 | 90.78 | 98.29 | 81.11 | 83.29 | -10.07% | 20,459,100 | |
| Aug 2026 | 94.87 | 115.52 | 86.00 | 92.62 | -4.03% | 16,922,400 | |
| Jul 2026 | 94.15 | 99.00 | 80.72 | 96.51 | +1.41% | 26,104,700 | |
| Jun 2026 | 57.53 | 97.78 | 53.62 | 95.17 | +62.60% | 34,440,900 | |
| May 2026 | 68.75 | 71.02 | 54.99 | 58.53 | -14.44% | 31,208,300 | |
| Apr 2026 | 49.82 | 91.00 | 49.00 | 68.41 | +39.47% | 44,414,900 | |
| Mar 2026 | 32.88 | 49.33 | 31.32 | 49.05 | +42.55% | 15,921,000 | |
| Feb 2026 | 34.28 | 36.53 | 31.00 | 34.41 | +0.53% | 6,445,600 | |
| 51 older periods: create a free account to see the whole history | |||||||
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Phase 2 Psoriasis Results Could Be A Big Moment For Oruka Therapeutics Stock (ORKA) (opens in a new tab) Simply Wall St. · 11 Nov 2026 01:17
- Oruka Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update (opens in a new tab) 09 Nov 2026 21:04
- Oruka Therapeutics Q3 EPS $(0.63) Misses $(0.60) Estimate (opens in a new tab) Benzinga · 09 Nov 2026 17:32
- Oruka Therapeutics to Participate in Multiple Upcoming Conferences (opens in a new tab) 03 Nov 2026 12:00
- Oruka Therapeutics Stock Gets A Lift From Psoriasis Trial Results (opens in a new tab) Simply Wall St. · 27 Oct 2026 07:06
- Oruka’s ORKA-001 Delivers 61% Complete Skin Clearance in Phase IIb Psoriasis Study (opens in a new tab) MarketBeat · 27 Oct 2026 03:02
- Oruka Therapeutics Soars 12% as Psoriasis Drug Clears Skin in 61% of High-Dose Patients: “A Paradigm Shift” (opens in a new tab) TIKR · 26 Oct 2026 17:45
- Oruka’s Psoriasis Treatment Could Generate $7B In Peak Sales, Says Guggenheim – ORKA Stock Heads For Best Day In Over 4 Months (opens in a new tab) Stocktwits · 26 Oct 2026 16:07
- Oruka Therapeutics (ORKA) Stock May Be Trading On A Rich Premium To Book Value (opens in a new tab) Simply Wall St. · 20 Oct 2026 07:10
- Oruka Therapeutics' Psoriasis Treatment Maintains 'Competitive Profile' After Positive Clinical Data, UBS Says (opens in a new tab) MT Newswires · 24 Sep 2026 18:02
- ORKA Stock Down 5% Despite Positive Week 28 Psoriasis Efficacy Data (opens in a new tab) Zacks · 24 Sep 2026 14:35
- What Oruka Therapeutics (ORKA)'s Phase 2a Psoriasis Data Means For Shareholders (opens in a new tab) Simply Wall St. · 24 Sep 2026 01:16
- Oruka Therapeutics Says Psoriasis Drug Shows Deepening Efficacy (opens in a new tab) Benzinga · 23 Sep 2026 14:49
- Oruka Therapeutics Shares Fall 5% After Week 28 ORKA-001 Trial Data (opens in a new tab) InvestorsHub · 23 Sep 2026 13:52
- ORKA Stock Up More Than 60% in 3 Months: Here's What You Should Know (opens in a new tab) Zacks · 28 Aug 2026 16:10
Headlines link to the original articles of the publishers shown; Kyvero does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 104.99 USD
- Market cap
- 7.1B
- Last dividend
- 19.3560 USD · 29 Aug 2024
- Exchange
- NasdaqGM
- Country
- United States
- Sector
- Healthcare
- Industry
- Biotechnology
- Currency
- USD
Dividends
| Ex-dividend date | Per share |
|---|---|
| 29 Aug 2024 | 19.3560 USD |
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Business growth Yearly growth of revenue and of earnings per share. | 8.8 / 25 No figures for this part: it counts as a cautious 35%. | — |
| Quality Return on equity, net margin and how stable the margins are. | 0.0 / 25 |
|
| Financial strength Net debt against operating earnings, interest cover and free cash flow. | 5.7 / 20 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 0.0 / 15 | — |
| Analysts How far the analysts' average target is from today's price. | 10.0 / 10 |
|
- The last full year was a loss
Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 70% of the figures (grade C). Warnings take 6 points off.
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio. How the score works
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| P/E (forward) | -36.42× | Weak | 14.16× |
| Price / book | 5.91× | Weak | 3.5× |
| EV / EBITDA | -33.92× | Weak | 11.19× |
| Free cash flow yield | -1.3% | Weak | 2.1% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | 0% | Weak | 54.9% |
| Operating margin | 0% | Weak | 5.8% |
| Net margin | 0% | Weak | 1.2% |
| Return on equity | -18.1% | Weak | 4.4% |
| Return on assets | -13.2% | Weak | 2.7% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | 0× | Good | 0.4× |
| Current ratio | 29.62× | Good | 2.64× |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Similar shares
Follow ORKA and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.